Michael Cordingley, PhD has more than 30 years of experience in pharmaceutical research. Mike brings to Antiva a wealth of experience in virology and innovative drug discovery and development across multiple therapeutic areas. He is currently CSO at Transposon Therapeutics, a clinical stage biotechnology company developing novel therapies for neurodegenerative, autoimmune and age related diseases Previously, he was President of Research and Site Head for Boehringer Ingelheim in Canada and a member of the global executive leadership team for Boehringer Ingelheim Research and Development. Mike has also held positions in Bristol Myers-Squibb and Merck Research Laboratories and has successfully led research organizations and teams working in numerous antiviral indications including HIV, HCV, human papilloma, and respiratory virus infections. Mike holds a PhD from the MRC Institute of Virology, University of Glasgow and an MA in Genetics from the University of Cambridge, England.

• 

  Senior Virology Adviser in Antivabio

  Stopping Cancer Before It Starts

• 

  Chief Scientific Officer (CSO) in Transposon Therapeutics

  Transformational therapies for neurodegenerative and aging-related diseases